发明授权
US09198951B2 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
有权
治疗剂量的神经调节蛋白或其后续剂量用于治疗或预防心力衰竭
- 专利标题： Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
- 专利标题（中）： 治疗剂量的神经调节蛋白或其后续剂量用于治疗或预防心力衰竭
-
申请号： US13904654申请日： 2013-05-29
-
公开(公告)号： US09198951B2公开(公告)日： 2015-12-01
- 发明人: Anthony O. Caggiano , Anindita Ganguly , Jennifer Iaci , Tom Parry
- 申请人： Acorda Therapeutics, Inc.
- 申请人地址： US NY Ardsley
- 专利权人： Acorda Therapeutics, Inc.
- 当前专利权人： Acorda Therapeutics, Inc.
- 当前专利权人地址： US NY Ardsley
- 代理机构： Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- 主分类号： A61K38/18
- IPC分类号： A61K38/18 ; C07K14/475
摘要：
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
公开/授权文献
信息查询
IPC分类:
